Alexander Gutmans is a partner at Walder Wyss since 2014. He advises national and international clients in the fields of commercial and corporate law, mergers & acquisitions, private equity, venture capital and financings as well as in the field of health care and life sciences in contractual and regulatory matters. As a notary of the canton Basel-Stadt he accompanies his clients in commercial register and real estate register transactions as well as German notarisations. Alexander Gutmans is also active as board member.

Born in 1967, Alexander Gutmans studied at the university of Basel (lic. iur. 1990; Dr. iur. 1995) and Lausanne an received a master’s degree from Yale Law School (LL.M. 1996). In 1993 Alexander Gutmans was admitted as attorney at law and in 2002 as notary. He started his professional career as legal counsel at Sandoz AG and after an assignment as foreign associate with an American law firm in New York he worked during 15 years as a lawyer for a leading Swiss law firm with offices in Basel, Bern and Zurich, during the last 11 years as a partner.

Alexander Gutmans‘ professional work languages are German and English. He also speaks French.

Significant Accomplishments

IFLR 1000 Rankings 2024 - Walder Wyss as a top-performing law firm ranked

SixPeaks Bio AG debuts with USD 110 million in Funding

Walder Wyss berät P&I Personal & Informatik AG beim Verkauf der Mirus Software AG an Alpha VCX

Axalta Coating Systems Group acquires André Koch AG

Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma

Nouscom Raises €67.5m ($72m) in Oversubscribed Series C Financing Round

Syz Capital und Saturnus Capital investieren in Capture Media

Zusammenschluss von SETEX und Datatex mit Elvaston

CONVOTIS startet mit der Übernahme der JMC Gruppe als Plattformunternehmen in den Schweizer IT Markt und stärkt seine Positionierung im Segment der Managed Services und digitalen Plattformlösungen.

LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections

IFLR 1000 Rankings - Walder Wyss as a top-performing law firm ranked

Pierre Fabre Laboratories acquires Vertical Bio AG

Das Familienunternehmen Henke-Sass, Wolf GmbH übernimmt die Zünd Präzisionsoptik AG

DSM and Firmenich have completed their EUR 35 bn merger, becoming the leading creation and innovation partner in nutrition, beauty and well-being

Alentis Therapeutics Closes USD 105m Series C Funding

BC Platforms Announces USD 20 Million Growth Financing led by Jolt Capital

groupe.id joins Elvaston

Versant Ventures launches Vector BioPharma with USD 30m Series A

Elvaston sells Magnolia International AG to GENUI

The Best Lawyers Awards 2023

BioVersys announces successful first closing of CHF 24.2 million Series C financing to develop clinical pipeline of novel AMR therapies

ImmunOs Therapeutics Raises USD 74 Million Series B Financing Round

DSM and Firmenich to merge in EUR 42bn transaction, becoming the leading creation and innovation partner in nutrition, beauty and well-being

Engimmune Therapeutics raises CHF 15.5m in Seed Financing

Versant Ventures launches Cimeio Therapeutics with USD 50m Series A

kooky sichert sich Finanzierung über EUR 6 Millionen

Memo Therapeutics Closes Series B Financing at CHF 37m Following Oversubscribed CHF 23m Extension

Avery Dennison acquires TexTrace

Alloy Therapeutics acquires deepCDR Biologics

GlycoEra CHF 45m Series A Financing

Perconex Holding GmbH kauft Flex Suisse AG

Polyphor and EnBiotix sign merger agreement and agreement on sale of Murapavadin

The Best Lawyers Awards 2022

Alentis Therapeutics erhält USD 67 Mio. im Rahmen einer Serie-B-Finanzierung

proLogistik Holding GmbH erwirbt XELOG AG

Calibre Scientific, Inc. acquires HUBERLAB.AG

Boehringer Ingelheim kauft NBE-Therapeutics für EUR 1,18 Milliarden

Noema Pharma Serie A-Finanzierungsrunde über CHF 54 Mio.

Synendos Therapeutics CHF 20m Series A Financing

VectivBio USD 110m Crossover Financing

Monte Rosa Therapeutics Serie B-Finanzierungsrunde über USD 96 Mio.

BioVersys Serie B-Finanzierungsrunde über CHF 19 Mio.

Versant Ventures lanciert Matterhorn Biosciences

Versant Ventures bringt Bright Peak Therapeutics auf den Markt

Walder Wyss berät BC Platforms im Hinblick auf die Series C Finanzierung über USD 15 Millionen sowie eine Partnerschaft mit IQVIA zum Ausbau der Datenanalytik im Bereich Genomik

ImmunOs Therapeutics AG raises CHF 15m in Series A Financing

Lindsay Goldberg übernimmt Bilcare Research Group

Boehringer Ingelheim erwirbt Amal Therapeutics SA

2020 Best Lawyers Awards

Seed Financing Round bei Premark Pharma GmbH

CHF 12.5 Million Finanzierungsrunde bei Alentis Therapeutics AG

Precision Surfacing Solutions kauft Wafer Geschäft von Meyer Burger

SHS investiert in Schweizer Life-Science-Unternehmen evitria AG

Cellestia Biotech AG: CHF 20 Millionen Series A Finanzierungsrunde

TOLREMO Therapeutics AG CHF 9 Mio. Serie A Finanzierungsrunde

Nouscom AG EUR 42 Mio. Serie B Finanzierungsrunde

BC Platforms CHF10 Mio. B Runde

BioVersys CHF 5.5 Mio. Serie A Runde

RWS acquires LUZ, Inc.

Acino veräussert sein Geschäft mit transdermalen Pflastern an Luye Pharma Group Ltd.

Bayer verkauft Diabetes-Care-Geschäft

Bayer und CRISPR Therapeutics gründen Genome Editing Joint Venture

Honeywell übernimmt Aviaso

Finanzierungsrunde von CRISPR Therapeutics

Avanade erwirbt KCS.net

P&I Personal & Informatik AG übernimmt Geschäftsbereich HR der Soreco AG

SVC-AG für KMU Risikokapital erwirbt Minderheitsbeteiligung an Stratpharma AG

Beschaffungsmöglichkeiten für Medizinprodukte im Lichte einer drohenden Versorgungslücke in der Schweiz
Einfuhr und Ausfuhr von Medizinprodukten in der Schwebe
§ 35 Einführung in die Grundlagen und die Systematik des schweizerischen Medizinprodukterechts